PHE in Journal of Managed Care & Specialty Pharmacy…
Journal of Managed Care & Specialty Pharmacy Article on Spending and Survival Within OCM-defined Episodes
PHE’s Jim Baumgardner led a study demonstrating that, for certain types of cancer, improved survival was associated with increased spending within oncology care episodes as defined by the Oncology Care Model. This research provides evidence that, in some cases, efforts to reduce spending may compromise the quality of care.
Health Policy Article on Expanding Cost-effectiveness Analysis in Non–small Cell Lung Cancer (NSCLC)
PHE’s Jason Shafrin led a study on the impact of expanding cost-effectiveness methods in the context of treating NSCLC patients with nivolumab. Under conventional cost-effectiveness methods, nivolumab’s net monetary benefit (NMB) was negative. Considering a broader societal perspective led to a doubling of the estimated benefits of nivolumab and a positive NMB for nivolumab.
An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference? Health Policy (2018).